Release date: 2007-08-17
In a groundbreaking development, US scientists have introduced a new tool for detecting bacterial membranes, offering hope in the fight against biofilm-related infections. This innovative cross-flow analysis device was created through a collaboration between students from the University of Northern Arizona and the University of Maryland. By combining biofilm-specific proteins with antibodies, the technology can identify unique antibodies present in a patient’s body, similar to how streptococcal infections are detected. This advancement allows medical professionals to diagnose biofilm-related diseases more quickly and initiate effective treatments earlier.
Most bacteria do not exist as isolated organisms but rather form complex structures known as "micro-clones." Within each micro-clone, the bacteria themselves occupy less than one-third of the total volume, while the remaining space is filled with a viscous substance called the "extracellular matrix," secreted by the bacteria. This matrix acts like a glue, binding thousands of bacterial micro-clones together to form a biofilm. These biofilms are highly resilient and difficult to eliminate, making them a major challenge in modern medicine.
It is estimated that around 70% of bacterial infections are linked to biofilms. These structures are particularly resistant to antibiotics and the body's immune defenses. Once a biofilm develops at an infection site, even a 100-fold increase in standard antibiotic dosage may not be sufficient to clear the infection. This resistance plays a significant role in the persistence of chronic and hard-to-treat infectious diseases. According to the U.S. Centers for Disease Control and Prevention, the annual cost of treating these types of infections in the United States exceeds $5 billion.
Jeff Laide, a researcher from the Center for Microbial Genetics at the University of Northern Arizona, emphasized the importance of this breakthrough. He stated, “Previously, healthcare providers lacked an effective method for diagnosing these infections, which often led to delayed treatment. With this new technology, we are hopeful that this issue will soon be resolved.†The research team is currently working on finalizing the details of the device and seeking partnerships with companies interested in commercializing the technology. Their goal is to bring this tool to market as a widely available medical device, ultimately improving patient outcomes and reducing the burden of biofilm-related infections.
—— Information from: China Medical Device NetworkActive Pharmaceutical Ingredients
VOLSEN is Manufacturers and suppliers of pharmaceutical raw materials,anti psychotic pharmaceutical chemicals,anti nootropics chemicals,anti coagulants bulk drugs, anti hepatitis and anti ulcerative pharmaceutical chemicals in China.
Our Major APIs Included Crude Oxiracetam which registered in KDMF, Amisulpride, Levosulpride, Rebamipide, Tenofovir Disoproxil Fumarate, Entecavir Monohydrate Micronized, Indometain, Ambroxol HCL, Bosentan Hydrate, Drospirenone, Sorafenib Tosylate, Tegaserod Maleate, Dolutegravir, Eltrombopag Olamine.Pazopanib HCL,Vilanterol,Dabrafenib,Trametinib,Axitinib,Umeclidinium Bromide, Although our APIs do not have GMP, but all productions are based on GMP environment, strictly according GMP standard.
Active Pharmaceutical Ingredients, Pharmaceutical Raw Materials, Pharmaceutical Chemicals, Productions APIS, Bulk Drugs
Taizhou Volsen Chemical Co., Ltd. , https://www.volsenchem.com